For moderate to severe patients 12+ years not adequately controlled with other systemic drugs, including biologics.1

RAPID
RELIEF2,3

Itch reduction* observed 2 days after 1st dose and measured at Week 16

Little to no itch measured at Week 16

75% skin improvement observed as early as Week 2 and measured at Week 16

ROBUST
RESPONSE1

90% skin clearance measured at Week 16

Clear to almost clear skin§ measured at Week 16

DURABLE
CONTROL4

Itch and skin improvement observed at ~3 years

WELL-STUDIED
SAFETY1,5-7

Clinical trial experience in >10,900 patients since 2012 across 6 approved indications

Safety rates up to 3 years in adults and pediatric patients 12+ years in AD8,9

SAFETY RATES

UP TO 5 YEARS8

NOW YOU CAN
hear
the unrelenting itch of AD

Commitment to exceptional access and patient support with

RINVOQ Complete logo.

RINVOQ Complete offers patients the resources and support they need to start and stay on track with their prescribed treatment plan.

for eligible patients who experience initial coverage delays or denials.

ONE-TO-ONE
SUPPORT

Connects patients with Nurse Ambassadors‡‡ and Insurance Specialists

ACCESS

Committed to exceptional access, with access specialists providing support to help patients get their medicine as prescribed.

AFFORDABILITY

Eligible, commercially insured patients may pay as little as $0/month on their RINVOQ prescription and can be reimbursed for the out-of-pocket costs of related lab tests and monitoring.§§

ONE PILL,
ONCE-DAILY1

RINVOQ is an oral, once-daily therapy.1

For adults <65 years and pediatric patients 12+ years weighing at least 40 kg (88 lb), initiate treatment with RINVOQ 15 mg once-daily in pediatric patients (≥12 years, ≥40 kg) and adults <65 years of age. If an adequate response is not achieved, consider increasing the dosage to 30 mg once-daily. Discontinue RINVOQ if an adequate response is not achieved with the 30 mg dose. Use the lowest effective dose needed to maintain response. For patients ≥65 years, patients receiving strong CYP3A4 inhibitors, and patients with severe renal impairment, the recommended dose of RINVOQ is 15 mg once-daily. Coadministration of RINVOQ with strong CYP3A4 inducers is not recommended.1

RINVOQ® (upadacitinib) packaging. RINVOQ® (upadacitinib) packaging. RINVOQ® (upadacitinib) packaging.

Want to learn about rapid skin clearance patients can see? In clinical studies
of RINVOQ, many patients achieved EASI 75 and vIGA 0/1 at Week 16.1

Itching to see more? See what patients experienced with RINVOQ in clinical trials.

Are your patients seeking treatment for the rash of atopic dermatitis?

Is itch a primary concern?

Safety is important to you. Want to know more about the safety profile of RINVOQ?

Want to know more about monitoring guidelines for RINVOQ?

RINVOQ Complete can help patients get the support they need to start
and stay on track with their prescribed treatment.

Familiar with Complete? RINVOQ Complete offers the same exceptional
AbbVie support you know and trust.

Connect with a Rep or sign up for more information